摘要
脂肪代谢障碍是一种常见的并发症,感染艾滋病毒的患者接受高活性抗逆转录病毒疗法。它的早期诊断,及时修改抗逆转录病毒治疗的关键。我们推测,在血浆中线粒体DNA可能是LD的艾滋病毒感染者的潜在标志物。在这项研究中,我们比较了艾滋病毒感染者和非HIV感染者血浆线粒体DNA水平,以探讨其潜在的诊断价值。 血浆总DNA从67个 HIV感染患者在基线和第12,24和30个月启动抗逆转录病毒治疗后提取。实时定量PCR法测定血浆中的线粒体DNA水平。脂肪代谢障碍是由医师评估存在脂肪萎缩或脂肪增生的一个或多个身体区域限定。在血浆中的线粒体DNA水平显著高于基线的艾滋病毒感染者比非HIV感染者(P <0)。一个月内67个病人中有30或33(49.2%)个至少有一个脂肪代谢障碍信号占2%。在24个月内,脂肪代谢障碍患者的平均血浆线粒体DNA水平显著高于那些没有脂肪代谢障碍,(P <0.001)。接收器工作曲线分析表明,利用等离子体线粒体DNA水平具有截止值> 5.09 log10拷贝/毫升)作为分子标记允许鉴定患者脂肪代谢障碍与64.2%的灵敏度和73.0%的特异性。我们的数据表明,线粒体DNA水平可能有助于指导治疗选择与指导HIV脂肪代谢障碍的风险。
关键词: 生物标志物,高效抗转录病毒治疗,人体免疫缺损病毒(HIV),脂肪代谢障碍,线粒体DNA,等离子体。
Current Molecular Medicine
Title:Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Volume: 15 Issue: 10
Author(s): Z. Dai, W. Cai, F. Hu, Y. Lan, L. Li, C. Chung, B. Caughey, K. Zhang and X. Tang
Affiliation:
关键词: 生物标志物,高效抗转录病毒治疗,人体免疫缺损病毒(HIV),脂肪代谢障碍,线粒体DNA,等离子体。
摘要: Lipodystrophy is a common complication in HIV-infected patients taking highly active antiretroviral therapy. Its early diagnosis is crucial for timely modification of antiretroviral therapy. We hypothesize that mitochondrial DNA in plasma may be a potential marker of LD in HIV-infected individuals. In this study, we compared plasma mitochondrial DNA levels in HIV-infected individuals and non-HIV-infected individuals to investigate its potential diagnostic value.
Total plasma DNA was extracted from 67 HIV-infected patients at baseline and 12, 24 and 30 months after initiating antiretroviral therapy. Real-time quantitative PCR was used to determine the mitochondrial DNA levels in plasma. Lipodystrophy was defined by the physician-assessed presence of lipoatrophy or lipohypertrophy in one or more body regions.
The mitochondrial DNA levels in plasma were significantly higher at baseline in HIV-infected individuals than in non-HIV-infected individuals (p<0.05). At month 30, 33 out of 67 patients (49.2%) showed at least one sign of lipodystrophy. The mean plasma mitochondrial DNA levels in lipodystrophy patients were significantly higher compared to those without lipodystrophy at month 24 (p<0.001). The receiver operating curve analysis demonstrated that using plasma mitochondrial DNA level (with cut-off value >5.09 log10 copies/ml) as a molecular marker allowed identification of patients with lipodystrophy with a sensitivity of 64.2% and a specificity of 73.0%.
Our data suggest that mitochondrial DNA levels may help to guide therapy selection with regards to HIV lipodystrophy risk.
Export Options
About this article
Cite this article as:
Z. Dai, W. Cai, F. Hu, Y. Lan, L. Li, C. Chung, B. Caughey, K. Zhang and X. Tang , Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART)., Current Molecular Medicine 2015; 15 (10) . https://dx.doi.org/10.2174/1566524016666151123114401
DOI https://dx.doi.org/10.2174/1566524016666151123114401 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Basal Bolus Dosing: A Clinical Experience
Current Diabetes Reviews Pneumonia in the Burn Patient
Current Respiratory Medicine Reviews Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment Approaches in Elderly Patients with Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Current Signal Transduction Therapy The Role of Melatonin in Rheumatic Diseases
Infectious Disorders - Drug Targets Medical Expert Systems
Current Bioinformatics Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Effects of an Outpatient Service Rehabilitation Programme in Patients Affected by Pulmonary Arterial Hypertension: An Observational Study
Cardiovascular & Hematological Disorders-Drug Targets The Effect of Adult and Pediatric Cardiopulmonary Bypass on Pharmacokinetic and Pharmacodynamic Parameters
Current Clinical Pharmacology A Review of Phytochemical and Pharmacological Studies of Inula Species
Current Bioactive Compounds Editorial [Hot Topic:Cell Metabolism as Therapeutic Target in Human Disease (Executive Guest Editors: Walter Malorni and Rosa Vona)]
Current Pharmaceutical Design Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine Colchicine: An Old Wine in a New Bottle?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Small Molecules as SIRT Modulators
Mini-Reviews in Medicinal Chemistry Emerging Role of Antioxidants in the Protection of Uveitis Complications
Current Medicinal Chemistry Allosteric Drugs and Seven Transmembrane Receptors
Current Topics in Medicinal Chemistry